TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Restriction on pulmonary function testing (TLC \<80%, FEV1/FVC ratio \> predicted or DLCO \< 80%)~2. Evidence of fibrosis on high resolution computed tomography of the chest.~3. Fibrosis on surgical lung biopsy if performed~4. Referral for pulmonary rehabilitation~Exclusion Criteria:~1. Participation in pulmonary rehabilitation in the past 24 months~2. Inability to complete 6 minute walk test or study questionnaires~3. Limitations other than dyspnea (e.g. arthritis) that affect ability to participate in pulmonary rehabilitation~4. Baseline 6 minute walk distance \> 400 meters~5. Planned change in medication treatment for lung disease during the course of pulmonary rehabilitation~6. Ejection fraction known to be \< 25%~7. Contraindications to pulmonary rehabilitation (clinically unstable, uncontrolled arrhythmia or hypertension, symptomatic or uncontrolled hypotension with systolic blood pressure of \< 95, active angina, unexplained syncope or worsening dizziness, limiting orthopedic or neurological disorders, psychiatric impairment that inhibits cooperation in the program)~8. FEV1/FVC \< 65%~9. Unable to provide informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lid Wiper Epitheliopathy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Sign Informed Consent document.~* Severe lid wiper epitheliopathy (upper lid) in either eye.~* Currently wearing spherical daily disposable soft contact lenses or daily wear soft contact lenses in both eyes with at least 3 months of contact lens wearing experience.~* Symptomatic as determined by the SPEED questionnaire.~* Willing to follow visit schedule.~* Habitual contact lens power with the range of -1.00 to -6.00 diopters (D) with best corrected distance visual acuity greater than or equal to 20/25 in each eye.~* Astigmatism less than or equal to 0.75D.~* Possess spectacles which provide visual acuity of at least 20/25 in each eye.~* Willing and able to complete daily diaries.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Eye injury within 12 weeks immediately prior to enrollment.~* Any ocular condition that would contraindicate contact lens wear.~* Any use of systemic or ocular medications that would contraindicate contact lens wear, as determined by the investigator.~* Currently wearing toric or multifocal soft contact lenses.~* Participation in a clinical study (including contact lens or contact lens care product) within the previous 30 days.~* Routinely sleeps in lenses for at least 1 night per week.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spectacles, Stage 1 (Type: EXPERIMENTAL): Spectacles per participant's habitual perscription worn for 2 weeks
- 1-DAY ACUVUE, Stage 1 (Type: ACTIVE_COMPARATOR): Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
- DAILIES TOTAL1, Stage 2 (Type: EXPERIMENTAL): Delefilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
- 1-DAY ACUVUE, Stage 2 (Type: ACTIVE_COMPARATOR): Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Standard risk of Recipients (CR1 or CR 2 of AML/ALL before transplantation except Ph+ ALL and T-ALL) of allogeneic stem cell transplantation with myeloablative conditioning regimens~* Standard risk of Recipients: CR1 or CR 2 of AML/ALL before transplantation~* Ph+ ALL, AML with t(8;21) and T-ALL were excepted~* Patients were at least 60 days post-transplantation~* Bone marrow monitoring was still Complete Remission (CR) and minor residual disease (MRD) was negative~* 15 years of age or older~* No serious infection~Exclusion Criteria:~* Exposure to any other clinical trials prior to enrollment~* Active malignant disease relapse~* Active, uncontrolled infection~* Inability to comply with IL-2 treatment regimen

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Interleukin-2 (Type: EXPERIMENTAL): Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
- controlled group (Type: NO_INTERVENTION): controlled standard risk leukemia received regular transplantation without IL-2 intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Implementing IntelliCare in Collaborative Care: A Quality Improvement Evaluation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in Rush Collaborative Care service~* Owns a personal smartphone~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment as Usual (TAU) (Type: ACTIVE_COMPARATOR): TAU will be the treatment that is provided through the Rush Collaborative Care program as part of their service
- IntelliCare (Type: EXPERIMENTAL): Patients will be offered IntelliCare as part of their care in the Rush Collaborative Care service. Patients who agree will download the IntelliCare app, which provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Treating Minor Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy in Unselected In Vitro Fertilization (IVF) Cases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normal Transvaginal Ultrasound~* No prior hysteroscopy~* Regular menstrual cycle~* Single embryo transfer~* BMI between 18 and 29~* Presence of both ovaries~* Primary or secondary infertility~* Women indicated for a first IVF/ICSI cycle~Exclusion Criteria:~* Recurrent miscarriage~* Prior hysteroscopic treatments~* Endometriosis \> AFS Stage II~* Meno-metrorrhagia (defined as any intermenstrual loss of blood)~* Submucosal/Intracavitary Fibroids taking more than 50% of the cavity~* Hydrosalpinx~* FSH/LH \> 12IU/L on day 3~* Polyps taking more than 50% of the cavity~* Severe adhesions \> grade II

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 36 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: NO_INTERVENTION): One or more of the predefined minor intra-uterine abnormalities have been detected, but not treated during hysteroscopy.
- 2 (Type: ACTIVE_COMPARATOR): One or more of the predefined minor intra-uterine abnormalities have been detected and treated during hysteroscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 to 17 years~* obesity~* high cholesterol~Exclusion Criteria:~* congenital heart diseases~* less than 6 or more than 17 years old

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities.
- Exercise (Type: EXPERIMENTAL): Participants receive a physical exercise plan to play at home

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Vibration to Improve Visual/Spatial Neglect in Patients Affected by Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* demonstrated visual/spatial neglect, as demonstrated by NIH Stroke Scale (NIHSS) and deficits in assessing tactile extinction and visuospatial neglect done on admission.~Exclusion Criteria:~* severe pain or skin disease at the posterior neck~* severe atherosclerosis of carotid arteries by an ultrasonic evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vibration to upper posterior neck muscles (Type: EXPERIMENTAL): Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
- Standard of care (Type: ACTIVE_COMPARATOR): Regular occupational therapy session

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Cognitive and Cardiovascular Health in the Elderly Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* free-living community-dwelling men and women aged ≥ 70 years,~* subjects free of clinical CVD related to atherosclerosis~* preserved basic activities of daily living (ADL = 6)~* without cognitive impairment (MMSE≥24)~Exclusion Criteria:~* subjects with clinical history of any of the following CVD diseases : coronary artery disease (angina, myocardial infarction, coronary revascularization), cerebrovascular disease (stroke, TIA, carotid revascularization), clinical peripheral artery disease (claudication, critical limb ischemia)~* subjects with neurodegenerative, locomotor and ophtalmological diseases unable to perform the cognitive tests~* subjects unable to give written informed consent.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardiovascular evaluation (Type: OTHER): Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Nautilus NeuroWaveTM to TCD or DSA for the Detection of Vasospasm

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects 18 years of age or older.~2. Subjects with subarachnoid hemorrhage who are receiving clinical and diagnostic surveillance for vasospasm.~3. Signed informed consent from the patient or the patient's Legally Authorized Representative~Exclusion Criteria:~1. Unstable medical illness such that recordings might interfere with medical care.~2. Presence of head bandages or brain monitors that might physically interfere with the NNW recording device.~3. Current hemicraniectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nautilus NeuroWaveTM recording (Type: None): Nautilus NeuroWaveTM recording 15 minute recording

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stromal Cells in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients;~* Aged 18 or older;~* Living-donor (related and unrelated, spouse/husband) kidney transplant recipients;~* Non-Human Leukocyte Antigen (HLA) identical with the donor (one or two haplotype mismatches);~* First kidney transplant;~* Capable of understanding the purpose and risk of the study;~* Written informed consent.~Exclusion Criteria:~* MSC donor positive for HIV-1, HIV-2, hepatitis B virus (HBV),hepatitis C virus (HCV), syphilis;~* Specific contraindication to MSC infusion;~* Any clinical relevant condition that might affect study participation and/or study results;~* Pregnant women and nursing mothers;~* Unwillingness or inability to follow study protocol in the investigator's opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesenchymal Stromal Cells (Type: EXPERIMENTAL): A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.~2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥40 years with moderate-severe COPD diagnosis according to the GOLD (The Global Initiative for Chronic Obstructive Lung Disease) strategy~* Patients who have symptomatic stable moderate to severe COPD diagnosis with post-bronchodilator FEV1/ Forced Vital Capacity (FVC) \<0.70, and FEV1 ≥30% and \<80% of predicted normal value at screening visit~* Current smokers or ex-smokers with a smoking history of at least 10 pack-years~* Patients who have no exacerbation within last 4 weeks~* Females patients with childbearing potential using effective birth control method~* Patients whose medication unchanged within least 4 weeks~* Patients who has a capability of communicate with investigator~* Patients who accept to comply with the requirements of the protocol~* Patients who signed written informed consent prior to participation~Exclusion Criteria:~* History of hypersensitivity to long acting beta-2 agonists or corticosteroids~* History of asthma or significant chronic respiratory diseases (e.g., interstitial lung diseases, significant bronchiectasis, etc.)~* Patients who had COPD exacerbation or lower respiratory track infections that required antibiotic, oral or parenteral corticosteroid treatment within 4 weeks prior to screening visit or during run-in period~* Use of immunosupresants or systemic corticosteroids within least 4 weeks~* History of severe cardiac arrhythmia or myocardial infarction within less than 6 months~* Significant or uncontrolled disease that may preclude participant from participating in the study~* Diognosis of cancer~* History of lung volume reduction operation~* Patients vaccinated with live attenuated vaccines within 2 weeks prior to screening visit or during run-in period~* Women patients who are pregnant or nursing~* History of allergic rhinitis and atopy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Salmeterol/Fluticasone Capsair® (Type: EXPERIMENTAL): Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
- Salmeterol/Fluticasone Diskus® (Type: ACTIVE_COMPARATOR): Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transmyocardial Laser Revascularization and Cardiovascular Magnetic Resonance Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 years of age or over~* Patients with medically refractory, severe, class III or IV angina based on the Canadian Cardiovascular Society angina scale as determined by a physician~* Ejection fraction 25% or greater~* Patients with significant ischemia in the myocardium and who are NOT candidates for treatment by direct coronary revascularization methods (i.e., CABG or PCI)~* Ability and willingness to consent and Authorization for use of PHI~Exclusion Criteria:~* Patient cannot undergo a surgical procedure or general anesthesia~* Patient not eligible for CMR study~* Severe unstable angina~* Q-wave MI within 3 weeks prior to TMR~* NQWMI within 2 weeks prior to TMR~* Decompensated heart failure (class III/IV) at the time of procedure~* Known increased bleeding risk~* Implanted pacemaker or defibrillator~* Clinically unstable arrhythmia~* Not able or willing to adhere to the study tests and procedures~* Inability or unwillingness to consent and Authorization for use of PHI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Patients (Type: OTHER): All patients undergo the same study procedures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of SAH~2. Presence of unsecured aneurysm~3. Patient age between 18 and 80 years~4. Hunt and Hess grade \<5 (non-sedated-paralyzed pt)~5. Glasgow Coma scale \>4 (non-sedated-paralyzed pt)~6. BP above the pre-specified upper limit set by MD~7. Patient has not received pressors or inotropes~8. Patient has not received IV anti-hypertensives for more than 5 minutes (sodium nitroprusside infusion should be stopped as clevidipine is started~9. Patient has given informed consent~Exclusion Criteria:~1. Patient is \<18 or \>80 years of age~2. Patient has Traumatic SAH~3. Patient has Perimesencephalic SAH~4. Hunt and Hess grade 5 (deeply comatose/ brain dead)~5. Glasgow Coma scale 3 or 4 (deeply comatose/brain dead)~6. Patient on pressors or anti-hypertensives for more than 5 minutes~7. SBP \< 90 mm Hg~8. Heart rate \>110~9. Patient with Left BBB~10. Patient with a permanent ventricular pacemaker~11. Known allergy to dihydropyridines or clevidipine~12. Known allergy to soy products, beans, eggs or egg products22. Patients with defective lipid metabolism or pathologic hyperlipidemia or lipid nephrosis~13. Acute pancreatitis, accompanied by hyperlipidemia~14. Severe aortic stenosis~15. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Clevidipine butyrate injectable emulsion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues